Medical devices, healthcare technology and the business of care
510(k) clearance · K262858

OxySight for MolecuLightDX+

MolecuLight, Inc. · Decision date Nov 5, 2026

MEDTECHLEDGER EXPLANATIONK262858

What did the FDA decide?

The FDA record for K262858 lists OxySight for MolecuLightDX+ from MolecuLight, Inc. (Toronto, Canada) under product code MUD, specialty Cardiovascular, as a Traditional 510(k) received 08/13/2026. The decision recorded is SESE, dated 11/05/2026, which for a 510(k) denotes clearance rather than PMA approval. The record does not describe the device's components, intended use, or what, if anything, changed relative to a prior clearance.

The same listing shows a summary document for this submission, but the excerpt provided does not include its contents, so the specific device description and any comparison to a predicate remain unknown. The Cardiovascular specialty and MUD product code are as recorded in the source; no clinical performance, indications, or labeling conclusions can be drawn from these fields alone. The related entries for K262842 and K262864 are separate submissions by other applicants and are not part of this decision.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Nov 5, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262858
Regulatory pathway
510(k) premarket notification
Product code
MUD
Decision code
SESE
Decision date
Nov 5, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Oximeter, Tissue Saturation.

Product code
MUD
FDA device class
2

FDA decision timeline

  1. K262858 received

    Application receipt date recorded by FDA.

  2. K262858 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

MolecuLight, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Toronto

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records